BioInvent to Present Clinical Data from its Two Leading Assets at ASCO 2024

• The two poster presentations will report -
  • first combination data from the Phase 1/2a study with BI-1808 in combination with MSD's anti-PD-1 therapy, KEYTRUDA (pembrolizumab), as well as an update on monotherapy arm
  • combination data from the Phase 1/2a study with BI-1206 in combination with KEYTRUDA for the treatment of patients with solid tumors
• Both BI-1808 and BI-1206 are first-in-class immunomodulatory agents with the potential to improve the efficacy of immune therapies and improve cancer outcomes
  • BI-1808, an anti-TNFR2 antibody capable of targeting Tregs and modifying the tumor microenvironment, that could represent a new class of checkpoint inhibitors
  • BI-1206, which blocks FcyRIIB, could overcome resistance to PD-1 inhibition
• Both posters will be presented at the American Society for Clinical Oncology (ASCO 2024) Annual Meeting taking place at the McCormick Place Convention Center in Chicago, Illinois from May 31st to June 4th

LUND, SWEDEN / ACCESSWIRE / April 24, 2024 / BioInvent International AB ("BioInvent") (STO:BINV), a biotech company focused on the discovery and development of novel and first-in-class immune-modulatory antibodies for cancer immunotherapy, today announced that two abstracts for its two leading assets, BI-1808 and BI-1206, have been selected for presentation at ASCO 2024.

"We are very pleased to be chosen to present data from our two lead candidates, BI-1808 (anti-TNFR2) and BI-1206 (anti-FccgRIIB) at ASCO 2024. Our research suggests that each of these first-in-class immunomodulatory agents have the potential to improve the efficacy of widely used immune therapies and improve cancer outcomes, said Martin Welschof, Chief Executive Officer of BioInvent. "These presentations represent the start of a data-rich year for BioInvent and build on the promising initial results from each program reported in 2023. We continue to advance the clinical development of both BI-1808 and BI-1206 and look forward to seeing the first Phase 2 data for BI-1808 and BI-1206 by year-end 2024".